Theravance in the News
Tuesday, June 2, 2009
Theravance to Present at Investor Conferences in June 2009
Thursday, April 30, 2009
Theravance to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
Friday, April 24, 2009
FDA Accepts for Review Theravance's Complete Response Submission for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Wednesday, April 22, 2009
Theravance Reports First Quarter 2009 Financial Results
Thursday, April 16, 2009
Theravance to Webcast 2009 Annual Meeting of Stockholders on April 24, 2009
Wednesday, April 8, 2009
Theravance to Report First Quarter 2009 Financial Results on April 22, 2009
Monday, April 6, 2009
Theravance Announces FDA Acceptance of Telavancin NDA for the Treatment of Hospital-Acquired Pneumonia
Tuesday, March 3, 2009
Theravance to Present at the Cowen and Company 29th Annual Health Care Conference
Thursday, February 26, 2009
Theravance Receives Complete Response Letter on the Telavancin New Drug Application for the Treatment of cSSSI
Thursday, February 12, 2009
Theravance Reports Fourth Quarter and Full Year 2008 Results
Wednesday, February 4, 2009
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma
Thursday, January 29, 2009
Theravance to Report Fourth Quarter and Full Year 2008 Financial Results on February 12, 2009
Monday, January 26, 2009
Theravance Submits U.S. NDA for Telavancin for the Treatment of Hospital-Acquired Pneumonia
Monday, December 22, 2008
GSK and Theravance Announce Positive Phase 2b Results for LABA '444 in the Treatment of COPD in the Horizon Development Programme
Tuesday, December 2, 2008
GSK and Theravance Announce Positive Phase 2b Results for LABA, '444 in the Horizon Asthma Development Programme
Wednesday, November 19, 2008
Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Wednesday, November 19, 2008
Trading in Theravance Common Stock Halted
Monday, November 17, 2008
Theravance Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee Meeting on Telavancin
Tuesday, November 4, 2008
Theravance to Present at the Credit Suisse Phoenix Healthcare Conference
Thursday, October 23, 2008
Theravance Reports Third Quarter 2008 Financial Results
Thursday, October 16, 2008
Telavancin Data to be Presented at Upcoming Scientific Conferences
Tuesday, October 14, 2008
Theravance Announces FDA Advisory Committee to Review Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Thursday, October 9, 2008
Theravance to Report Third Quarter 2008 Financial Results on October 23, 2008
Thursday, August 21, 2008
Theravance to Present at the Thomas Weisel Partners Healthcare Conference
Thursday, July 24, 2008
Theravance Reports Second Quarter 2008 Financial Results
Medicines That Make a Difference
®
Media
650-808-3784
corpcomm at theravance dot com
More Press Releases
©2009 Theravance, Inc. Theravance, the Theravance logo and Medicines That Make a Difference are registered trademarks of Theravance, Inc. Trademarks, trade names or service marks of other companies appearing on this website are the property of their respective owners. All rights reserved.
Terms of Use
Website Admin Contact
Theravance Contact
Site Map
